Sol-Gel Technologies Ltd. SLGL 深 沪
等待开盘 07-06 09:30:00 美东时间
74.01
+2.020
+2.81%
华盛通- 最 高74.79
- 今 开73.80
- 成交量 2.87万股
- 最 低 71.57
- 昨 收 71.99
- 总市值 2.42亿
- 52周最高 97.97
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 7.6163
- 委 比 -73.91%
- 总股本 326.90万
- 历史最高 210.00
- 量 比 1.29
- 振 幅 4.47%
- 历史最低 3.34
- 每 手 1
- 风险率 24.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
Mizuho Initiates Coverage On Sol-Gel Technologies with Outperform Rating, Announces Price Target of $285
Mizuho analyst Uy Ear initiates coverage on Sol-Gel Technologies (NASDAQ:SLGL) with a Outperform rating and announces Price Target of $285.
06-24 18:07
Sol-Gel Technologies Q1 EPS $(1.31) Beats $(1.84) Estimate, Sales $108.000K Miss $900.000K Estimate
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.84) by 28.8 percent. This is a 59.06 percent increase over losses of $(3.20) per share
05-28 20:38
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during T...
03-25 01:05
BRIEF-Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering
BRIEF-Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering March 23 (Reuters) - Sol Gel Technologies Ltd SLGL.O : SOL-GEL TECHNOLOGIES LTD. ANNOUNCES PRICING OF OVERSUBSCRIBED UNDERWRITTEN OFFERING SOL GEL TECHNOLOGIES LTD - SOL-GEL TECHNOLOGIES PRICES 459,112 SHARES A
03-24 09:39
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. announced the pricing of an underwritten offering of 459,112 ordinary shares at $72.00 per share, raising approximately $33.1 million. The funds will support the development of SGT-610, a Phase 3 topical hedgehog inhibitor for Gorlin syndrome, with potential applications in high-frequency basal cell carcinoma. The offering includes participation from notable investors and is expected to close on March 25, 2026. Sol-Gel i...
03-24 01:38
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Sol-Gel Technologies Ltd. filed its annual report on Form 20-F for 2025, available on the SEC website and its investor relations site. The company is advancing rare skin disease therapies, including SGT-610, a Phase 3 topical hedgehog inhibitor for Gorlin syndrome patients, and SGT-210, a topical EGFR inhibitor. Sol-Gel also markets FDA-approved dermatology products TWYNEO® and EPSOLAY®.
03-19 12:53
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition
Ellomay Capital Ltd. announced that its major shareholders, S. Nechama Investments, Kanir Joint Investments, and Anat Raphael, have sold their 45.9% stake to O.Y. Nofar Energy Ltd. Following the sale, two board members, Anita Leviant and Ehud Gil, resigned immediately, while the chairman, Ben Sheizaf, will step down within 30 days. Two new independent directors, Odelya Ohayon and Gilad Mamlok, were appointed to fill the vacancies, with Mamlok joi...
03-04 21:32
Opaleye Management Inc. reports acquisition of Sol-Gel Technologies common shares
Opaleye Management Inc. reports acquisition of Sol-Gel Technologies common shares Opaleye Management Inc. reported an acquisition of common shares of Sol-Gel Technologies Ltd. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT
02-19 05:06
